Measurements using an N-terminal assay showed elevated concentration of plasma tau in patients with AD and MCI, and reported high accuracy for discriminating MCI, AD, and the control group [discovery cohort: AUC (MCI) = 0.88, AUC (AD) = 0.96; validation cohort: AUC (MCI) = 0.79, AUC (AD) = 0.75] (Chen et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.